Dick P, Ferrero E
Br J Clin Pharmacol. 1983;15 Suppl 3(Suppl 3):419S-425S. doi: 10.1111/j.1365-2125.1983.tb02132.x.
1 We report the results of a comparative clinical trial of a new antidepressant drug fluvoxamine (a specific re-uptake inhibitor of 5-hydroxytryptamine (5-HT)) with chlorimipramine. Thirty-two patients with mixed depression received one or the other drug at the same daily dosage of 150 mg. 2 In both drug groups there was an overall clinically significant improvement for all items on the Hamilton Rating Scale for Depression (67% improvement in both groups). 3 In the chlorimipramine group there were more digestive symptoms and anticholinergic effects; the difference with the fluvoxamine group approached statistical significance. 4 No clinically important effects of either treatment were observed on heart-rate or blood pressure.
我们报告了一种新型抗抑郁药物氟伏沙明(一种5-羟色胺(5-HT)特异性再摄取抑制剂)与氯米帕明对比临床试验的结果。32例混合性抑郁症患者以每日150mg的相同剂量服用其中一种药物。
两个药物组在汉密尔顿抑郁评定量表的所有项目上总体均有临床上显著的改善(两组改善率均为67%)。
氯米帕明组有更多的消化系统症状和抗胆碱能效应;与氟伏沙明组的差异接近统计学显著性。
两种治疗方法均未观察到对心率或血压有临床重要影响。